2-Cyano-N-thiophen-2-ylmethyl-acetamide | 347324-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-Cyano-N-thiophen-2-ylmethyl-acetamide
• 英文别名: 2-Cyano-N-(2-thienylmethyl)acetamide；2-cyano-N-(thiophen-2-ylmethyl)acetamide
• CAS: 347324-95-2
• 化学式: C₈H₈N₂OS
• mdl: MFCD00119993
• 分子量: 180.23
• InChiKey: GNUSPUIOGRNHSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-Cyano-N-thiophen-2-ylmethyl-acetamide 、 2-氨基苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以67%的产率得到2-amino-N-(thiophen-2-ylmethyl)quinoline-3-carboxamide
  参考文献：
  名称：

  Cyanoacetamides (IV): Versatile One-Pot Route to 2-Quinoline-3-carboxamides

  摘要：

  Cyanoacetic acid derivatives are the starting materials for a plethora of multicomponent reaction (MCR) scaffolds. Herein, we describe scope of a valuable general protocol for the synthesis of arrays of 2-aminoquinoline-3-carboxamides from cyanoacetamides and 2-aminobenzaldehydes or heterocyclic derivatives via a Friedlander reaction variation. In many cases, the reactions involve a very convenient work up by simple precipitation and filtration. More than 40 new products are described. We foresee our protocol and the resulting derivatives becoming very valuable to greatly expanding the scaffold space of cyanoacetamide derivatives.

  DOI：

  10.1021/co3000133
• 作为产物：
  描述：

  2-噻吩甲胺 、 氰乙酸甲酯 生成 2-Cyano-N-thiophen-2-ylmethyl-acetamide
  参考文献：
  名称：

  Cyanoacetamides (IV): Versatile One-Pot Route to 2-Quinoline-3-carboxamides

  摘要：

  Cyanoacetic acid derivatives are the starting materials for a plethora of multicomponent reaction (MCR) scaffolds. Herein, we describe scope of a valuable general protocol for the synthesis of arrays of 2-aminoquinoline-3-carboxamides from cyanoacetamides and 2-aminobenzaldehydes or heterocyclic derivatives via a Friedlander reaction variation. In many cases, the reactions involve a very convenient work up by simple precipitation and filtration. More than 40 new products are described. We foresee our protocol and the resulting derivatives becoming very valuable to greatly expanding the scaffold space of cyanoacetamide derivatives.

  DOI：

  10.1021/co3000133

文献信息

• Modulators of LXR
  申请人：——

  公开号：US20030181420A1

  公开（公告）日：2003-09-25

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节核受体活性的杂环化合物，包括肝X受体（LXR）和孤儿核受体。在某些实施方式中，这些化合物是N-取代吡啶酮。
• [EN] NOVEL ARGINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS D'ARGINASE
  申请人：UNIV GRONINGEN

  公开号：WO2020249821A1

  公开（公告）日：2020-12-17

  The present invention relates to novel arginase inhibitors of formula (I). These novel compounds are useful in the treatment of diseases that are associated with arginase activity, such as asthma, allergic rhinitis and COPD (chronic obstructive pulmonary disease).

  本发明涉及式(I)的新型精氨酸酶抑制剂。这些新型化合物在治疗与精氨酸酶活性相关的疾病方面具有用途，如哮喘、过敏性鼻炎和慢性阻塞性肺疾病（COPD）。
• Aminoisoxazole derivatives active as kinase inhibitors
  申请人：Cavicchioli Marcello

  公开号：US20050059657A1

  公开（公告）日：2005-03-17

  Compounds (I) which are aminoisoxazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明涉及氨基异噁唑衍生物(I)或其药学上可接受的盐，以及包含它们的药物组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• Discovery and structure–activity relationships of small molecules that block the human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein–protein interaction
  作者：Zhaolin Wang、Cara Fraley、Adam R. Mezo

  DOI：10.1016/j.bmcl.2013.01.014

  日期：2013.3

  The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen. (c) 2013 Elsevier Ltd. All rights reserved.
• AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1435948A1

  公开（公告）日：2004-07-14